Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
TIGIT encodes a member of the PVR (poliovirus receptor) family of immunoglobin proteins. Additionally we are shipping TIGIT Proteins (23) and TIGIT Kits (5) and many more products for this protein.
Showing 10 out of 37 products:
Mouse (Murine) Monoclonal TIGIT Primary Antibody for ICFC - ABIN2665414
Stanietsky, Simic, Arapovic, Toporik, Levy, Novik, Levine, Beiman, Dassa, Achdout, Stern-Ginossar, Tsukerman, Jonjic, Mandelboim: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. in Proceedings of the National Academy of Sciences of the United States of America 2009
Show all 3 references for ABIN2665414
Mouse (Murine) Monoclonal TIGIT Primary Antibody for ELISA (Detection), ELISPOT (Detection) - ABIN2658413
Levin, Taft, Brandt, Bucher, Howard, Chadwick, Johnston, Hammond, Bontadelli, Ardourel, Hebb, Wolf, Bukowski, Rixon, Kuijper, Ostrander, West, Bilsborough, Fox, Gao, Xu, Ramsdell, Blazar, Lewis: Vstm3 is a member of the CD28 family and an important modulator of T-cell function. in European journal of immunology 2011
Show all 3 references for ABIN2658413
Mouse (Murine) Monoclonal TIGIT Primary Antibody for ELISA (Capture) - ABIN2662886
Yu, Harden, Gonzalez, Francesco, Chiang, Irving, Tom, Ivelja, Refino, Clark, Eaton, Grogan: The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. in Nature immunology 2008
Show all 3 references for ABIN2662886
TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization.
implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 (show CD226 Antibodies) for the same ligand, CD155 (show PVR Antibodies)
These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells
This study shows that HBZ (show HBZ Antibodies)-induced TIGIT plays a pivotal role in attenuating host immune responses and shaping a microenvironment favorable to human T-cell leukemia virus type 1.
a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer.
Human regulatory T cells expressing the receptors TIGIT and CD226 (show CD226 Antibodies) display widely divergent phenotypes in regard to expansion and activation.
TIGIT and PD-1 (show PDCD1 Antibodies) blockade additively increased proliferation, cytokine production, and degranulation of tumor-antigen-specific CD8 (show CD8A Antibodies) T cells and CD8 (show CD8A Antibodies) TILs. TIGIT and PD-1 (show PDCD1 Antibodies) regulate the expansion and function of these T cells in melanoma.
the TIGIT/FCRL3 (show FCRL3 Antibodies) combination allows reliable identification of Helios (show ZNFN1A2 Antibodies)(+) Treg cells even in highly activated conditions in vitro as well as in PBMCs of autoimmune patients.
The results identify a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleatum to inhibit immune cell activity via TIGIT.
Findings suggest that TIGIT is a key checkpoint inhibitor of chronic antiviral and antitumor responses through impairing CD226 (show CD226 Antibodies) function when disrupting its homodimerization.
TIGIT negatively regulates inflammation by altering macrophage phenotype.
TIGIT signaling in Tregs directs their phenotype. It suppresses antitumor immunity via Tregs and not CD8 (show CD8A Antibodies)+ T cells. TIGIT+ Tregs upregulated TIM-3 (show HAVCR2 Antibodies) expression in tumor tissue. TIM-3 (show HAVCR2 Antibodies) and TIGIT synergized to suppress antitumor immune responses.
TIGIT is a safeguard molecule to improve liver regeneration through negatively regulating NK-hepatocyte crosstalk.
TIGIT/PVR (show PVRL2 Antibodies) ligation signaling mediates suppression of IFN-gamma (show IFNG Antibodies) production via the NF-kappaB (show NFKB1 Antibodies) pathway.
expressed on a Treg cell subset that selectively suppresses Th1 (show HAND1 Antibodies) and Th17 cells but not Th2 cells
found that TIGIT was up-regulated selectively on NK cells and protected against liver injury in an acute adenovirus infection model in both an NK cell- and Kupffer cell-dependent manner
findings show that TIGIT is expressed by NK cells, that it interacts specifically with PVR (show PVRL2 Antibodies) and possibly with an additional unknown ligand found on PBMCs and that these interactions lead to the inhibition of NK-cell activities
animals deficient in Vstm3 are more sensitive to autoimmune challenges indicating that this new member of the CD28 (show CD28 Antibodies) family is an important regulator of T-cell responses
TIGIT can act directly on T cells by attenuating T cell receptor-driven activation signals; loss of TIGIT results in hyperproliferative T cell responses and increased susceptibility to autoimmunity.
This gene encodes a member of the PVR (poliovirus receptor) family of immunoglobin proteins. The product of this gene is expressed on several classes of T cells including follicular B helper T cells (TFH). The protein has been shown to bind PVR with high affinity\; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses.
T-cell immunoreceptor with Ig and ITIM domains
, V-set and immunoglobulin domain containing 9
, V-set and immunoglobulin domain-containing protein 9
, V-set and transmembrane domain containing 3
, V-set and transmembrane domain-containing protein 3
, Washington University cell adhesion molecule